NCT02633007 - A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

May 31, 2016

Conditions

Asthma

Interventions

DRUG

CVT-301 (levodopa inhalation powder)

Capsules containing l-dopa, designed to deliver ldopa to the lung using the CVT-301 inhaler. CVT-301 will be administered 3 times, 4 hours apart, and 1 hour following the administration of carbidopa.

DRUG

Carbidopa

Administered orally according to the carbidopa dosing schedule.

OTHER

Placebo

Placebo of CVT-301 is administered in the same way as the investigational product, except that it does not contain l-dopa.

Trial Locations (3)

32117

Site 002, Daytona Beach

75247

Site 003, Dallas

02747

Site 001, North Dartmouth